Abstract

Background:Monoclonal antibodies targeting interleukin 5 (IL-5) and IL-5α receptor have proven to be effective in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).Objectives:The aim of this study was to compare...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Alessandra Bettiol ...
Arthritis & Rheumatology | VOL. 74
Alessandra Bettiol, et. al.Alessandra Bettiol ...
30 Dec 2021
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study
Alessandra Bettiol ...
The Lancet Rheumatology | VOL. 5
Alessandra Bettiol, et. al.Alessandra Bettiol ...
06 Nov 2023
AB1258 EFFECTIVENESS OF DUPILUMAB ON REFRACTORY CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CLINICAL AND CYTOLOGICAL STUDY
F Davanzo ... A Doria
Annals of the Rheumatic Diseases | VOL. 83
F Davanzo, et. al.F Davanzo ... A Doria
01 Jun 2024
P136 Glucocorticoid sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
Bd Kent ... G D’Ancona
-
Bd Kent, et. al.Bd Kent ... G D’Ancona
16 Nov 2018
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.